Persson A V, Persson C A
Am J Surg. 1985 Oct 8;150(4A):50-3.
We have outlined our treatment for acute DVT with thrombolytic agents. We prefer to use thrombolytic agents unless a specific contraindication is present. Both heparin and thrombolytic agents carry the risk of bleeding. In our opinion, the long-term results of restoring the deep venous system anatomically and physiologically are more likely if thrombolysis is the chosen therapy. Heparin therapy simply arrests the problem and relies on the development of sufficient venous collateral pathways, recanalization, or both to improve venous return. The short-term results (the first 6 months) of thrombolytic therapy and heparin are similar. The results of prospective, randomized studies comparing standard anticoagulation versus lytic therapy have documented improved long-term venous function in patients receiving thrombolytic therapy.
我们已经概述了使用溶栓药物治疗急性深静脉血栓形成的方法。除非存在特定的禁忌症，否则我们更倾向于使用溶栓药物。肝素和溶栓药物都有出血风险。我们认为，如果选择溶栓治疗，从解剖学和生理学角度恢复深静脉系统的长期效果更有可能实现。肝素治疗只是控制问题，依赖于充分的静脉侧支通路的形成、再通或两者兼而有之来改善静脉回流。溶栓治疗和肝素治疗的短期结果（前6个月）相似。比较标准抗凝治疗与溶栓治疗的前瞻性随机研究结果表明，接受溶栓治疗的患者长期静脉功能得到改善。
